# IBS Clinical Care Gaps and the Potential of Future Therapeutics based on Peripheral Visceral Afferent Modulation. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ibs-pain-management-gaps-future-therapeutics/ > **Published:** 2026-04-14T01:02:18-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:22:31-04:00 > **Clinical Summary:** Explore IBS pain management gaps and the potential of future therapeutics targeting peripheral visceral afferent modulation for improved patient care. --- CED Clinical Relevance  #88High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🔬 Evidence Watch  |  CED Clinic IbsPainGastrointestinalVisceral HypersensitivityPeripheral Neuropathy Journal Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association Study Type Randomized Trial Population Human participants Why This Matters This review highlights a critical gap in IBS management where current treatments inadequately address visceral pain, the most debilitating symptom for patients. It identifies promising peripheral nerve targets that could revolutionize IBS care by directly modulating pain signals at the dorsal root ganglion level. Clinical Summary This comprehensive review examined unmet needs in IBS treatment and evaluated peripheral visceral afferent modulation as a therapeutic approach. The authors analyzed physiological pathways of visceral pain transmission through dorsal root ganglion neurons and reviewed preclinical evidence for receptor-targeted therapies. Current IBS management focuses on bowel dysfunction or central nervous system modulation, leaving visceral pain undertreated. The review identified specific DRG receptors as promising therapeutic targets based on rodent models showing efficacy in visceral hypersensitivity. Dr. Caplan’s Take “While this mechanistic framework is intellectually compelling, I remain cautious about translating rodent visceral pain models to human IBS complexity. The heterogeneity of IBS presentations suggests that peripheral afferent modulation may benefit specific patient subsets rather than representing a universal solution.” Clinical Perspective 🧠 Clinicians should recognize that current IBS [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) remains suboptimal and consider this research as foundational for future targeted therapies. Patients experiencing inadequate pain relief with conventional treatments may benefit from understanding that novel peripheral nerve-targeted approaches are in development, though clinical applications remain investigational. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20IBS%20Clinical%20Care%20Gaps%20and%20the%20Potential%20of%20Future%20Therapeutics%20based%20on%20Periphe...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41974246/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41974246/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20IBS%20Clinical%20Care%20Gaps%20and%20the%20Potential%20of%20Future%20Therapeutics%20based%20on%20Periphe...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41974246/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41974246/](https://pubmed.ncbi.nlm.nih.gov/41974246/) Table of Contents - [FAQ](#FAQ)[What is the greatest unmet clinical need in IBS treatment?](#What_is_the_greatest_unmet_clinical_need_in_IBS_treatment) - [How do pain signals travel from the gut to the brain in IBS patients?](#How_do_pain_signals_travel_from_the_gut_to_the_brain_in_IBS_patients) - [What makes peripheral visceral afferent modulation a promising therapeutic approach?](#What_makes_peripheral_visceral_afferent_modulation_a_promising_therapeutic_approach) - [What evidence supports targeting DRG receptors for IBS pain relief?](#What_evidence_supports_targeting_DRG_receptors_for_IBS_pain_relief) - [How does this research approach differ from current IBS treatments?](#How_does_this_research_approach_differ_from_current_IBS_treatments) - [Related](#Related) ## FAQ #### What is the greatest unmet clinical need in IBS treatment? According to this research, the greatest need in IBS management is safe and effective treatment of pain. Current therapies focus primarily on bowel dysfunction or central neuromodulators, leaving significant gaps in addressing the visceral pain component that severely impacts patients’ [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/). #### How do pain signals travel from the gut to the brain in IBS patients? Pain transmission occurs through multiple pathways: physiological stimuli travel via vagal and pelvic parasympathetic pathways, while noxious pain stimuli are conducted through visceral afferents and the spinal cord. The cell bodies of these peripheral visceral afferents are located in the dorsal root ganglion (DRG), making them important therapeutic targets. #### What makes peripheral visceral afferent modulation a promising therapeutic approach? Peripheral visceral afferents contain specific receptors in their DRG cell bodies that can be pharmacologically targeted to relieve pain. This approach offers the potential for more targeted pain relief with fewer systemic [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) compared to central neuromodulators, addressing the critical need for safer IBS [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/). #### What evidence supports targeting DRG receptors for IBS pain relief? The review summarizes evidence from both rodent models of visceral hypersensitivity and randomized controlled trials in IBS patients. These studies demonstrate that pharmacological approaches directed at receptors expressed by DRGs can effectively reduce pain or pain surrogates, supporting this as a viable therapeutic strategy. #### How does this research approach differ from current IBS treatments? Unlike current management that focuses on bowel dysfunction or central nervous system modulation, this approach targets peripheral pain pathways at the level of visceral afferents. This peripheral targeting strategy may offer more specific pain relief while potentially avoiding the systemic [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) associated with centrally-acting medications. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [IBS Clinical Care Gaps and Future Therapeutics via Peripheral Visceral Afferent Modulation](https://cedclinic.com/peripheral-visceral-afferent-modulation-ibs-pain/) A detailed exploration of peripheral visceral afferent modulation as a promising approach to address IBS pain and clinical care gaps. [Read More](https://cedclinic.com/peripheral-visceral-afferent-modulation-ibs-pain/) [NY Advances Cannabis Research In First Study On CBD, THC, And IBD](https://cedclinic.com/ny-advances-cannabis-research-in-first-study-on-cbd-thc-and-ibd/) Insights into [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) focusing on CBD and THC effects on inflammatory bowel disease, relevant to IBS therapeutic developments. [Explore Study](https://cedclinic.com/ny-advances-cannabis-research-in-first-study-on-cbd-thc-and-ibd/) [Cannabis-based interventions might help a little with neuropathic pain – Study Summary](https://cedclinic.com/cannabis-neuropathic-pain-relief-modest-benefits/) Summary of research on cannabis-based interventions for [neuropathic pain](https://cedclinic.com/cannabis-for-pain-relief/), offering context for novel pain management strategies. [Learn More](https://cedclinic.com/cannabis-neuropathic-pain-relief-modest-benefits/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).